Dr. Nedrow's research interests include the development of radiopharmaceuticals for targeted alpha therapy and imaging applications; synthesis and evaluation of peptides modified for labeling with copper-64, gallium-68, and lutetium-177 for use as molecular imaging and therapeutic agents; the development and application of PSMA-targeted radiotheranostics; and the development and evaluation of prostate specific membrane antigen (PSMA) targeted phosphoramidate and phosphate inhibitors, modified to deliver an imaging payload to PSMA positive cells in vitro and in vivo.
Pharmacokinetics, micro-scale distribution and dosimetry of alpha-emitter labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. Jessie R Nedrow*, Anders Josefsson*, Sunju Park, Tom Bäck, Robert F. Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, and George Sgouros. European Journal of Nuclear Medicine and Molecular Imaging, accepted.
Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHer2 mice: Characterization and use in a model of metastatic breast cancer. Sunju Park, Jessie R. Nedrow, Anders Josefsson, and George Sgouros. Oncotarget, accepted.
Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model. Jessie R. Nedrow, Anders Josefsson, Sunju Park, Sagar Ranka, Sanchita Roy, and George Sgouros. Journal of Nuclear Medicine, accepted.
Emerging Radiometals for PET Imaging. Jessie R. Nedrow and Carolyn J. Anderson. Encyclopedia of Inorganic and Bioinorganic Chemistry, Online @ 2011-2016 John Wiley & Sons, Ltd.
Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Anders Josefsson*, Jessie R. Nedrow*, Sunju Park, Sangeeta Ray Banerjee, Andrew Rittenbach, Fabien Jammes, Benjamin Tsui, George Sgouros. Cancer Research, 2016, 76(2): 472-9.